“The federal government is actively preventing the effective distribution of monoclonal antibody treatments in the U.S. The sudden suspension of multiple monoclonal antibody therapy treatments from distribution to Florida removes a health care provider’s ability to decide the best treatment options for their patients in this state,” he said. “This shortsightedness is especially evident given that the federal government effectively prohibited states from purchasing these monoclonal antibodies and serving their populations directly.”